MeiraGTx HoldingsSTU:328 56 EBIT per Share is €-1.16 as of Mar. 2026. GuruFocus rates STU:328 with a GF Score™ of 56/100 and a GF Value™ of €20.56 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,174 Biotechnology companies, MeiraGTx Holdings ranks better than 56.22% on this metric.
MeiraGTx Holdings's EBIT per Share for the
three
months ended in Mar. 2026 was €-0.46.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €-1.16.
During the past 3 years, the average EBIT per Share Growth Rate was 20.00% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 0.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for MeiraGTx Holdings's EBIT per Share or its related term are showing as below:
STU:328'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -19 Med: -12.6 Max: 26.3
Current: 20
During the past 10 years, the highest 3-Year average EBIT per Share Growth Rate of MeiraGTx Holdings was 26.30% per year. The lowest was -19.00% per year. And the median was -12.60% per year.
STU:328's 3-Year EBIT Growth Rate is ranked better than 56.22% of 1174
companies
in the Biotechnology industry
Industry Median: 15.4
vs STU:328: 20.00
MeiraGTx Holdings (STU:328) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
MeiraGTx Holdings EBIT per Share Related Terms
MeiraGTx Holdings EBIT per Share Historical Data
* Premium members only.
The historical data trend for MeiraGTx Holdings's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.16
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MeiraGTx Holdings (STU:328) has a EBIT per Share of €-1.16 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on MeiraGTx Holdings and its competitors. According to the industry distribution chart, MeiraGTx Holdings ranks #514 out of 1174 companies in the Biotechnology industry, placing it in the top 43.8%.
Is MeiraGTx Holdings' EBIT per Share too high?
MeiraGTx Holdings' current EBIT per Share is €-1.16. Based on the distribution chart, MeiraGTx Holdings ranks #514 out of 1174 companies in the Biotechnology industry, which is above the industry midpoint. Overall, MeiraGTx Holdings has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MeiraGTx Holdings' EBIT per Share compare to XNCR and WVE?
According to the Biotechnology industry distribution chart, MeiraGTx Holdings ranks #514 out of 1174 companies for EBIT per Share. This puts MeiraGTx Holdings in the upper half of its industry. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,174 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on MeiraGTx Holdings and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MeiraGTx Holdings's current EBIT per Share is €-1.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MeiraGTx Holdings stock overvalued right now?
Based on GuruFocus' analysis, MeiraGTx Holdings (STU:328) is currently considered Possible Value Trap. The stock's GF Value™ is €20.56, compared to a current price of €12.10 — trading 41.1% below its estimated fair value. The current EBIT per Share is €-1.16. MeiraGTx Holdings' overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For MeiraGTx Holdings (STU:328), the current EBIT per Share is €-1.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MeiraGTx Holdings (STU:328) Overvalued in 2026?
Based on GuruFocus' analysis, MeiraGTx Holdings stock appears to be undervalued.
The current stock price of €12.10 is trading 41.1% below its estimated GF Value™ of €20.56.
GuruFocus considers MeiraGTx Holdings to be Possible Value Trap.
Key valuation signals for STU:328:
EBIT per Share: €-1.16
GF Value™: €20.56 vs. price of €12.10 (41.1% below fair value)
No single metric tells the full story. See the STU:328 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
56GF Score
Get the complete analysis for STU:328
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:328 has been successfully added to your 
